This is the standing evidence sheet for Gilead Sciences (GILD): the yardsticks BullScope computes from official SEC filings and market prices. It refreshes whenever a new edition of our research is published, and it is impersonal by design, every reader sees the same page. Nothing here is investment advice; it is the evidence, organized.
The price tag: what buyers pay per dollar of profit
Today the market pays about $21.0 for each $1 of Gilead Sciences’s annual profit (a price-to-earnings ratio of 21.0). Across its own past decade the typical price tag was 21.0, which puts today at roughly the 50th percentile of the company’s own history.
The tape: what the stock itself has done
- Last price: $151.17 (end-of-day market data as of the edition date · methodology) · 3% below its 52-week high
- Past 6 months: +8.8% · past 12 months: +27.8%
- Day-to-day temperament: jumpy (annualized volatility 26%)
The filed record: straight from the annual reports
| Fiscal year | Revenue | Growth | Operating margin | EPS |
|---|---|---|---|---|
| FY2021 | $27.3B | +10.6% | 36.3% | $4.93 |
| FY2022 | $27.3B | -0.1% | 26.9% | $3.64 |
| FY2023 | $27.1B | -0.6% | 28.0% | $4.5 |
| FY2024 | $28.8B | +6.0% | 5.8% | $0.38 |
| FY2025 | $29.4B | +2.4% | 34.0% | $6.78 |
The road ahead: filed results vs published expectations
| FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | |
|---|---|---|---|---|---|
| Net sales ($B) | 27.1 | 28.8 | 29.4 | 30.5 to 32.0 | 31.5 to 34.5 |
| Net sales growth (%) | +5.5 | +6.3 | +2.1 | 4 to 9 | 2 to 8 |
| Operating margin (%) | 28.0 | 5.9 | 34.0 | 28.0 to 33.0 | 30.0 to 36.0 |
| Diluted EPS ($) | 4.50 | 0.38 | 6.78 | 4.54-7.29 | 4.00 to 8.50 |
Columns marked A are actual filed results; E columns are the published consensus ranges the current price is being weighed against.
The four gauges: from the latest edition
BullScope coverage of Gilead Sciences
- Gilead’s Ledger: A Business Growing Faster Than Its Balance Sheet Suggests
- Gilead’s Books Say One Thing. The Price Tag Says Another. Here’s What the Filings Actually Show.
Read the full report on Gilead Sciences in the BullScope Terminal → It opens with this company loaded.
Edition date: 2026-08-21. This page updates when a new edition is published. Sources: SEC EDGAR filings, Nasdaq prices; computed by BullScope’s published methodology.
